CN115137778A - Application of traditional Chinese medicine composition in preparation of medicine for improving and/or treating rhinitis - Google Patents
Application of traditional Chinese medicine composition in preparation of medicine for improving and/or treating rhinitis Download PDFInfo
- Publication number
- CN115137778A CN115137778A CN202210293173.1A CN202210293173A CN115137778A CN 115137778 A CN115137778 A CN 115137778A CN 202210293173 A CN202210293173 A CN 202210293173A CN 115137778 A CN115137778 A CN 115137778A
- Authority
- CN
- China
- Prior art keywords
- rhinitis
- radix
- traditional chinese
- chinese medicine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for improving and/or treating rhinitis. The traditional Chinese medicine composition is mainly prepared from notopterygium root, radix angelicae pubescentis, poria cocos, radix sileris, schizonepeta rhizoma Ligustici Chuanxiong, radix Platycodi, bupleuri radix, radix Peucedani, fructus Aurantii, and Glycyrrhrizae radix. The traditional Chinese medicine composition can obviously improve symptoms of rhinocnesmus, nasal discharge, sneeze and the like caused by rhinitis, and can be used for treating the rhinitis caused by various factors.
Description
Technical Field
The invention relates to a traditional Chinese medicine composition and application thereof, in particular to a traditional Chinese medicine composition and application thereof in preparing a medicine for improving and/or treating rhinitis, and belongs to the technical field of traditional Chinese medicines.
Background
Rhinitis, an inflammatory disease of the nasal cavity, is inflammation of the mucous membrane of the nasal cavity caused by viruses, bacteria, allergens, various physicochemical factors and certain systemic diseases. The main pathological changes of rhinitis are congestion, swelling, exudation, hyperplasia, atrophy or necrosis of the nasal mucosa. The common symptoms of rhinitis include nasal obstruction, rhinorrhea, epistaxis, sneezing, hyposmia, headache, etc. Mild rhinitis nasal obstruction is relatively light and is discontinuous nasal obstruction or nasal obstruction with alternation of nasal cavities at two sides, and severe rhinitis can be persistent nasal obstruction; the allergic rhinitis is characterized by a large amount of clear water-like nasal discharge, the acute rhinitis or the chronic rhinitis can have sticky nasal discharge and purulent nasal discharge, the purulent nasal discharge can be white, yellow or grass green, and the purulent nasal discharge is mainly caused by the nasosinusitis; the epistaxis can only have a small amount of bloodstains and can also be jet bleedings; sneezing is the most common of allergic rhinitis, and severe rhinitis causes a decline or loss of olfaction.
The traditional Chinese medicine considers that rhinitis (nasal obstruction) is mainly caused by dysfunction of viscera and invasion of pathogenic qi to nasal orifices due to exogenous wind-cold. This disease is usually refractory: firstly, the healthy qi is deficient and the pathogenic factors linger, and secondly, the exogenous pathogenic factors can cause the pathogenic factors to be long-term, and the pathogenic fire burns the body fluid to cause turbid phlegm to block the nasal orifices. Therefore, the dysfunction of the five zang-organs and six fu-organs is the root, mainly including the deficiency of the lung, spleen and kidney. Spleen pertains to earth and is the mother of lung, and spleen deficiency can cause the generation and transformation of lung and lung deficiency; kidneys belong to water, and metal water mutually generates, so the key points are to warm and nourish lung qi, invigorate spleen and replenish qi, and warm and nourish nephritis.
The traditional Chinese medicine considers that the essence of rhinitis is that the vital qi is insufficient and the rhinitis is weak to expel pathogenic factors. Traditional Chinese medicine divides rhinitis patients into two types, namely excess syndrome and deficiency syndrome: (1) wind-heat syndrome of lung meridian: adopts the therapeutic principles of promoting blood circulation and inducing resuscitation, dispelling wind and clearing heat; (2) pattern of heat accumulation in the gallbladder: the treatment principles of resolving dampness and dredging orifices and clearing away gallbladder-fire should be adopted; (3) syndrome of dampness-heat in spleen channel: it should be treated according to the principles of inducing resuscitation with aromatics and clearing spleen-fire to eliminate dampness. Deficiency syndrome: (1) syndrome of lung qi deficiency and cold: the treatment principle is that qi is benefited, lung is warmed, and cold is dispelled to dredge the orifice; (2) spleen qi deficiency syndrome: the treatment principle is that the traditional Chinese medicine composition clears away dampness and promotes diuresis, and benefits qi and strengthens spleen; (3) syndrome of insufficient marrow sea: it is based on the principle of tonifying kidney, replenishing essence, benefiting brain and stopping nasal discharge.
Disclosure of Invention
The inventor explains that the invention is further developed on the basis of the existing products of Jingfang granules and Jingfang mixture, the new application of the invention is derived from feedback of use of employees of companies, and part of employees with rhinitis history unexpectedly find that rhinitis symptoms are obviously reduced or eliminated during the period of drinking the Jingfang granules and the Jingfang mixture to prevent cold. Based on employee feedback, applicants have further investigated the use of Jingfang preparations in the improvement and/or treatment of rhinitis.
The first purpose of the invention is to provide a traditional Chinese medicine composition for improving and/or treating rhinitis, which comprises notopterygium root, radix angelicae pubescentis, poria cocos, radix sileris, schizonepeta, ligusticum wallichii, platycodon grandiflorum, radix bupleuri, radix peucedani, fructus aurantii and liquorice;
the Chinese medicinal composition comprises the following medicinal materials in part by weight:
50-100 parts of schizonepeta, 50-100 parts of divaricate saposhnikovia root and 50-100 parts of notopterygium root
50-100 parts of pubescent angelica root, 50-100 parts of bupleurum root, 50-100 parts of peucedanum root
50-150 parts of ligusticum wallichii, 50-150 parts of fructus aurantii, 50-150 parts of poria cocos
50-100 parts of platycodon grandiflorum and 5-50 parts of liquorice.
Preferably, the first and second liquid crystal materials are,
75 parts of schizonepeta, 75 parts of divaricate saposhnikovia root and 75 parts of notopterygium root
75 parts of pubescent angelica root, 75 parts of Chinese thorowax root and 75 parts of whiteflower hogfennel root
75 parts of ligusticum wallichii, 75 parts of fructus aurantii and 75 parts of poria cocos
75 parts of platycodon grandiflorum and 25 parts of liquorice.
The rhinitis is inflammation of nasal mucosa caused by one or more factors;
specifically, the rhinitis includes but is not limited to one or more of viral infection, genetic factors, nasal mucosa susceptibility, antigen substances and systemic diseases.
Further, rhinitis may be caused by sympathetic nerve excitation, drug induction, hormonal responses, hypothyroidism, mood, climate changes, irritants, systemic diseases, malnutrition, and the like.
The systemic diseases can be anemia, diabetes, rheumatism, tuberculosis, heart, liver, nephropathy, superior vena cava syndrome, vegetative nerve functional disturbance, chronic constipation, etc.
The drug inducement may be aspirin, non-steroidal anti-inflammatory drugs, and other drugs.
Viral infections may be caused by rhinoviruses, influenza and parainfluenza viruses, as well as streptococcus pneumoniae, haemophilus influenzae.g.
Further, the rhinitis includes acute rhinitis, chronic rhinitis, atrophic rhinitis, caseous rhinitis, rhinitis medicamentosa, allergic rhinitis, vasomotor rhinitis, fungal sinusitis, eosinophilic non-allergic rhinitis, hyperreflexia rhinitis, and complications caused by rhinitis.
Chronic rhinitis includes, but is not limited to, chronic simple rhinitis, chronic rhinitis sicca, chronic hypertrophic rhinitis.
Allergic rhinitis includes, but is not limited to, seasonal rhinitis, perennial rhinitis, intermittent rhinitis.
The second purpose of the invention is to provide the application of the traditional Chinese medicine composition in preparing the medicine for improving and/or treating rhinitis complications.
Complications resulting from rhinitis include, but are not limited to, orbital parietal osteomyelitis, periostitis, orbital parietal subperiosteal abscess, intraorbital cellulitis, intraorbital abscess, retrobulbar neuritis, epidural abscess, subdural abscess of dura mater, purulent meningitis, brain abscess, cavernous sinus thrombophlebitis, otitis media, conjunctivitis, acute pharyngitis, laryngitis, tracheitis, bronchitis, dacryocystitis, nasal vestibulitis, sinusitis, emphysema, pulmonary heart disease, asthma, nasal polyps, and other infections.
The third purpose of the invention is to provide a preparation prepared from the traditional Chinese medicine composition and pharmaceutically acceptable auxiliary materials, which is mainly a traditional Chinese medicine preparation; preferably, the Chinese medicinal preparation is a clinically acceptable oral preparation; further, the clinically acceptable oral preparation is one or more of granules, oral liquid, syrup, tablets, capsules, pills, powder, microcapsules and paste.
The invention also provides application of the Jingfang preparation prepared from the traditional Chinese medicine composition in preparing a medicine for treating rhinitis.
The Jingfang preparation can be Jingfang granules, jingfang mixture and the like.
Compared with the prior art, the invention has the following remarkable technical effects:
(1) The traditional Chinese medicine composition can obviously inhibit EOS inflammatory factors and reduce the content levels of Ig E, ECP and NO in serum of a model rat, thereby improving inflammatory response and effectively treating rhinitis;
(2) The traditional Chinese medicine composition can obviously relieve the symptoms of nasal itching, nasal discharge, sneeze and the like caused by rhinitis.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
The present invention will be described in further detail by way of examples for the purpose of making the objects and technical solutions of the present invention clearer, but it should not be construed that the scope of the above-described subject matter of the present invention is limited to the following examples. Such alterations and modifications are intended to be included herein within the scope of this disclosure as determined by those skilled in the art to which the invention pertains and by the annexed claims.
EXAMPLE 1 preparation of granules
Prescription:
75g of schizonepeta, 75g of divaricate saposhnikovia root, 75g of incised notopterygium rhizome, 75g of pubescent angelica root, 75g of Chinese thorowax root, 75g of whiteflower hogfennel root and 75g of common hogfennel root
75g of ligusticum wallichii, 75g of fructus aurantii, 75g of poria cocos, 75g of platycodon grandiflorum and 25g of liquorice;
the preparation method comprises the following steps:
step A: respectively distilling herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and respectively distilling the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the bitter orange obtained in the step A into a 25% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled herba schizonepetae obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs with water twice for 1.5 hours each time, combining decoctions obtained in the two times, filtering and concentrating into thick paste for later use;
step E: and D, mixing the percolate obtained in the step C and the thick paste obtained in the step D, standing, filtering, concentrating into clear paste, adding a proper amount of cane sugar, uniformly mixing, preparing into granules, drying, adding the volatile oil obtained in the step A, and uniformly mixing to obtain the traditional Chinese medicine.
Example 2 preparation of granules
Prescription:
50g of schizonepeta, 50g of divaricate saposhnikovia root, 50g of incised notopterygium rhizome, 50g of pubescent angelica root, 50g of Chinese thorowax root, 50g of whiteflower hogfennel root and 50g of whiteflower hogfennel root
50g of ligusticum wallichii, 50g of fructus aurantii, 50g of poria cocos, 50g of platycodon grandiflorum and 25g of liquorice.
The preparation method is the same as example 1.
Example 3 preparation of cocktails
Prescription:
97g of schizonepeta, 97g of divaricate saposhnikovia root, 97g of incised notopterygium rhizome, 97g of pubescent angelica root, 97g of Chinese thorowax root, 97g of whiteflower hogfennel root
97g of ligusticum wallichii, 97g of fructus aurantii, 97g of poria cocos, 97g of platycodon grandiflorum, 32.4g of liquorice;
the preparation method comprises the following steps:
respectively distilling herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, fructus Aurantii, rhizoma Ligustici Chuanxiong and radix Peucedani to extract volatile oil, and collecting the distilled water solution; mixing rhizoma Ligustici Chuanxiong, fructus Aurantii dregs and Poria with distilled water solution to obtain 25% ethanol as solvent, percolating, collecting percolate, and recovering ethanol under reduced pressure. Decocting the residue of the rest five Chinese medicinal materials, bupleuri radix, radix Platycodi and Glycyrrhrizae radix with water for three times, filtering, mixing filtrates, concentrating to about 1300ml, mixing with percolate, standing, filtering, concentrating to about 1000ml, adding sodium benzoate 3g and the above volatile oil, stirring, and adding water to 1000 ml.
EXAMPLE 4 Capsule preparation
Prescription:
75g of schizonepeta, 75g of divaricate saposhnikovia root, 75g of incised notopterygium rhizome, 75g of pubescent angelica root, 75g of Chinese thorowax root, 75g of whiteflower hogfennel root and 75g of common hogfennel root
75g of ligusticum wallichii, 75g of fructus aurantii, 75g of poria cocos, 75g of platycodon grandiflorum and 25g of liquorice;
the preparation method comprises the following steps:
step A: respectively distilling herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and respectively distilling to obtain residue, and water solution of rhizoma Ligustici Chuanxiong and fructus Aurantii;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 30% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and the residue of fructus Aurantii, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled schizonepeta obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs with water twice, each time for 1.5 hours, combining decoctions obtained in the two times, filtering and concentrating into thick paste for later use;
step E: and D, mixing the percolate obtained in the step C and the thick paste obtained in the step D, standing, filtering, concentrating into clear paste, adding a proper amount of cane sugar, uniformly mixing, granulating, drying, adding the volatile oil obtained in the step A, uniformly mixing, granulating, drying, crushing and encapsulating to obtain the capsule.
EXAMPLE 5 tablet preparation
Prescription:
75g of schizonepeta, 75g of divaricate saposhnikovia root, 75g of incised notopterygium rhizome, 75g of pubescent angelica root, 75g of Chinese thorowax root, 75g of whiteflower hogfennel root and 75g of common hogfennel root
75g of ligusticum wallichii, 75g of fructus aurantii, 75g of poria cocos, 75g of platycodon grandiflorum and 25g of liquorice;
the preparation method comprises the following steps:
step A: respectively distilling herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and respectively distilling the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain water solution;
and B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 15% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled herba schizonepetae obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs with water twice for 1.5 hours each time, combining decoctions obtained in the two times, filtering and concentrating into thick paste for later use;
step E: and D, mixing the percolate obtained in the step C and the thick paste obtained in the step D, standing, filtering, concentrating into clear paste, adding a proper amount of cane sugar, uniformly mixing, granulating, drying, adding the volatile oil obtained in the step A, uniformly mixing, granulating, adding a proper amount of auxiliary materials, uniformly mixing, and tabletting to obtain the traditional Chinese medicine.
EXAMPLE 6 pellet preparation
Prescription:
75g of schizonepeta, 75g of divaricate saposhnikovia root, 75g of incised notopterygium rhizome, 75g of pubescent angelica root, 75g of Chinese thorowax root, 75g of whiteflower hogfennel root and 75g of common hogfennel root
75g of ligusticum wallichii, 75g of fructus aurantii, 75g of poria cocos, 75g of platycodon grandiflorum and 25g of liquorice;
the preparation method comprises the following steps:
step A: respectively distilling herba Schizonepetae, radix Saposhnikoviae, notopterygii rhizoma, radix Angelicae Pubescentis, radix Peucedani, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain volatile oil, and respectively distilling the residue, rhizoma Ligustici Chuanxiong, and fructus Aurantii to obtain water solution;
and B, step B: b, preparing the distilled water solution of the ligusticum wallichii and the fructus aurantii obtained in the step A into a 25% ethanol solution for later use;
and C: mixing Poria, the distilled rhizoma Ligustici Chuanxiong obtained in step A, and fructus Aurantii residue, percolating with the ethanol solution obtained in step B, and collecting percolate;
step D: decocting radix bupleuri, platycodon grandiflorum, liquorice, the distilled herba schizonepetae obtained in the step A, divaricate saposhnikovia root, notopterygium root, radix angelicae pubescentis and radix peucedani dregs with water twice for 1.5 hours each time, combining decoctions obtained in the two times, filtering and concentrating into thick paste for later use;
step E: and D, mixing the percolate obtained in the step C and the thick paste obtained in the step D, standing, filtering, concentrating into clear paste, adding a proper amount of cane sugar, uniformly mixing, preparing into granules, drying, adding the volatile oil obtained in the step A, uniformly mixing, drying, crushing, sieving, adding 40-60 g of refined honey and a proper amount of water, pelleting and drying to obtain the traditional Chinese medicine composition.
Pharmacological experiments
The inventor carries out related pharmacodynamic experimental study to prove the efficacy of the traditional Chinese medicine composition for treating rhinitis. It should be noted that the drugs selected by the pharmacodynamic tests described below are representative formulations, dosage forms and drugs obtained by the preparation method of the invention; the inventor also carries out pharmacodynamic experiments, and the experimental results show that the medicines obtained by other formulas, formulations and preparation methods have the same or similar effects, but the purposes of space limitation are not listed.
In addition, the pharmacodynamic experiments described below only take part of animal models as examples to verify the efficacy of the traditional Chinese medicine composition, and only show the pharmacodynamic experiment results of the traditional Chinese medicine composition for treating allergic rhinitis, and for other types of rhinitis and rhinitis complications mentioned in the invention, the inventor also performs related pharmacodynamic experiments, and the experiment results show that the traditional Chinese medicine composition has the same or similar effects, and the pharmacodynamic experiment results are not listed.
The inventor explains that the following experimental studies are carried out on the basis of the safety of the drug proved by acute toxicity tests and long-term toxicity tests, and the administration dose in the experimental studies is within a safe dose range.
The traditional Chinese medicine composition has the treatment effect on allergic rhinitis model rats
1 Material
1.1 Experimental drugs and reagents
1.1.1 medicaments
The granules obtained in examples 1 and 2 of the invention and the oral liquid obtained in examples 3 and 4;
cetirizine hydrochloride tablets ("beifen", national standard H20000379, lunanfibrate pharmaceuticals, ltd);
ovalbumin (OVA);
aluminum hydroxide gel.
1.1.2 dosage
Example 1 granules: 2.02g/kg (low dose), 4.05g/kg (medium dose), 8.10g/kg (high dose);
example 2 granules: 4.05g/kg;
example 3 mixture: 2.70ml/kg (low dose), 5.40ml/kg (high dose);
cetirizine hydrochloride tablets: 0.90mg/kg.
1.2 Experimental animals:
SD rat, SPF grade, 180-220g, laboratory animal license number: SYXK (lu) 2018 0008, supplied by lumnan pharmaceutical group ltd, was acclimatized for 1 week under standard conditions prior to the experiment.
2. Method of producing a composite material
2.1 grouping of Experimental animals
The SD rats 90 were randomly divided into a blank group, a model group, a cetirizine hydrochloride group, three dose groups of example 1 (high, medium, and low), an example 2 group, and two dose groups of example 3 (high and low), each group containing 10 rats.
2.2 mode of making molds
Establishing a model group, a cetirizine hydrochloride group, an Ovalbumin (OVA) sensitization model of three dose groups of example 1 (high, medium and low), an example 2 group and an example 3 (high and low) two dose groups: on day 1, 0.5ml of sterile normal saline containing 10 mu g of OVA and 1mg of aluminum hydroxide gel is intraperitoneally injected to carry out basic sensitization, on day 5, 0.5ml of sterile normal saline containing 0 mu g of OVA is intraperitoneally injected to enhance sensitization, on day 6, 50 mu l of 2mg/ml OVA is dripped into the nose 1 time every day, the rats are continuously stimulated for 14 days, the numbers of sneezing and nose scratching and the running nose are observed, and 80 rats are successfully modeled. The blank group was subjected to pseudo-sensitization and pseudo-challenge using sterile physiological saline in the same manner.
2.3 administration of drugs
The rats in each administration group were gavaged with the corresponding drugs, and the rats in the blank group and the model group were gavaged with an equal amount of physiological saline for 1 time per day for 7 days.
3 observation index
3.1 rat status determination
Allergic reaction behavior was observed in each group of rats with nasal itching, nasal discharge and sneezing, and the rats were scored 24 hours after the last challenge.
TABLE 1 Scoring criteria for allergic nasal symptoms in rats
| Symptoms and signs | Mild degree of disease | Of moderate degree | Severe degree |
| Itching of nose | Make sure the head touch several times | Both of them between | Rubbing at four places |
| Nasal discharge | A small amount of nasal discharge is seen | Nasal discharge passing through the midline | Noodle with running nose |
| Zxfoom | 1-3 times | 3-9 times | More than 9 times |
| Scoring | 1 minute (1) | 2 is divided into | 3 points of |
3.2 nasal mucosa histopathology experiment
Decalcification treatment is carried out on nasal septum mucosa tissues for 72 hours, dehydration, embedding, slicing and baking are carried out, hematoxylin-eosin (HE) staining is carried out, histological changes are observed under a high-power microscope, and the total number changes of eosinophilic granulocyte (EOS) are recorded.
3.3 detection of cellular immune factors
After the rats in each group are excited for 24 hours for the last time, venous blood is taken from the rats, serum samples are taken, and the contents of total immunoglobulin E (T-IgE), eosinophil Cationic Protein (ECP) and Nitric Oxide (NO) in the serum are respectively detected.
3.4 statistical treatment
By usingSPSS22.0 software is used for statistical analysis and data measurement
The results are shown in the following table, wherein the comparison among the groups is carried out by adopting one-factor analysis of variance, and the analysis between the two groups is carried out by adopting an independent sample T test mode. With P<A difference of 0.05 is statistically significant.
4. Results and conclusions
4.1 behavioral State in rats
The comparison of the allergic reaction behavior scores of the rhinocnesmus, the nasal discharge and the sneeze of the rats in each group (see table 2) shows that the difference is statistically significant (P is less than 0.05) when the model group is compared with a blank group, a cetirizine hydrochloride group, three dose groups of example 1 (high, medium and low), two dose groups of example 2 and example 3 (high and low); the differences between the three dose groups of example 1 (high, medium and low), example 2 and example 3 (high and low) compared with the cetirizine hydrochloride group were not statistically significant (P > 0.05). The nasal allergy symptoms of rats in the three dose groups of example 1 (high, medium and low), example 2 and example 3 (high and low) are shown to be significantly alleviated, statistically indistinguishable from the cetirizine hydrochloride group.
TABLE 2 Scoring of allergic nasal symptoms in rats
Note: p < 0.01 compared to blank;
p < 0.01 compared to model group.
4.2 statistics of nasal secretion EOS in rats
TABLE 3 rat nasal secretion EOS count
Note: p < 0.05 compared to blank, @ P＜0.01；
p < 0.01 compared to model group.
4.3 the content of Ig E, ECP, NO in rat serum
TABLE 4 comparison of the serum Ig E, ECP, NO content in rats of each group after administration
Note: in contrast to the blank group, @ P＜0.05，*P＜0.01；
in contrast to the model set, # P＜0.01。
in conclusion, the traditional Chinese medicine composition can obviously reduce the quantity of nasal secretion EOS of rats and reduce the content levels of serum Ig E, ECP and NO of model rats, shows that the traditional Chinese medicine composition can play a role in anti-inflammation and immunoregulation, and effectively treats rhinitis.
Claims (10)
1. A Chinese medicinal composition comprising Notopterygii rhizoma, radix Angelicae Pubescentis, poria, radix Saposhnikoviae, herba Schizonepetae, rhizoma Ligustici Chuanxiong, radix Platycodi, bupleuri radix, radix Peucedani, fructus Aurantii, and Glycyrrhrizae radix is used for preparing medicine for improving and/or treating rhinitis.
2. The use of claim 1, wherein said rhinitis includes, but is not limited to, acute rhinitis, chronic rhinitis, atrophic rhinitis, caseous rhinitis, rhinitis medicamentosa, allergic rhinitis, vasomotor rhinitis, fungal sinusitis, eosinophilic non-allergic rhinitis, and hyper-reflex rhinitis.
3. The use according to claim 1, wherein the rhinitis may be caused by one or more of viral infection, genetic factors, nasal mucosal predisposition, antigenic substances, systemic disease.
4. The use of claim 2, wherein the chronic rhinitis includes but is not limited to chronic simple rhinitis, chronic rhinitis sicca, chronic hypertrophic rhinitis.
5. The use according to claim 2, wherein the allergic rhinitis includes but is not limited to seasonal rhinitis, perennial rhinitis, intermittent rhinitis.
6. Use of the Chinese medicinal composition according to claim 1 in the preparation of a medicament for improving and/or treating rhinitis complications.
7. The use of claim 6, wherein the rhinitis complications include, but are not limited to, orbital parietal osteomyelitis, periostitis, infraorbital osteomyelitis, intraorbital cellulitis, intraorbital abscess, retrobulbar neuritis, epidural abscess, subdural abscess, purulent meningitis, brain abscess, cavernous sinus thrombophlebitis, otitis media, conjunctivitis, acute pharyngitis, laryngitis, tracheitis, bronchitis, dacryocystitis, nasal vestibulitis, sinusitis, emphysema, cor pulmonale, asthma, nasal polyps, other infections.
8. The use of any one of claims 1-7, wherein the traditional Chinese medicine composition comprises the following raw materials:
preferably, the first and second liquid crystal materials are,
9. the use of claim 8, wherein the composition is formulated with pharmaceutically acceptable excipients; preferably, the preparation includes, but is not limited to, granules, mixtures, oral liquids, syrups, tablets, capsules, pills, powders, microcapsules, and ointments.
10. Application of Jingfang preparation in preparing medicine for improving and/or treating rhinitis and its complication is provided.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110338989 | 2021-03-30 | ||
| CN2021103389897 | 2021-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115137778A true CN115137778A (en) | 2022-10-04 |
Family
ID=83406812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210293173.1A Pending CN115137778A (en) | 2021-03-30 | 2022-03-23 | Application of traditional Chinese medicine composition in preparation of medicine for improving and/or treating rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115137778A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105876088A (en) * | 2014-10-20 | 2016-08-24 | 胡金明 | Influenza-preventing feed additive with pure traditional Chinese medicines |
| CN112386635A (en) * | 2020-09-23 | 2021-02-23 | 鲁南制药集团股份有限公司 | Application of Jingfang preparation in preparing medicine for treating new coronary sequelae and preparation method thereof |
-
2022
- 2022-03-23 CN CN202210293173.1A patent/CN115137778A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105876088A (en) * | 2014-10-20 | 2016-08-24 | 胡金明 | Influenza-preventing feed additive with pure traditional Chinese medicines |
| CN112386635A (en) * | 2020-09-23 | 2021-02-23 | 鲁南制药集团股份有限公司 | Application of Jingfang preparation in preparing medicine for treating new coronary sequelae and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 夏承志;阳永明;王旭;: "中西医结合治疗单纯疱疹性角膜炎36例临床观察" * |
| 张洁;韩棉梅;何小琦;张霄霖;: "辨证分型治疗急性上呼吸道感染105例临床体会" * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003227336C1 (en) | Composition for heart disease, method to prepare same and uses thereof | |
| CN103877244A (en) | Medicinal composition for treating headache and preparation method thereof | |
| CN101214288B (en) | Traditional Chinese medicinal composition for treating hepatitis and its preparation | |
| CN103705754A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus | |
| WO2019077400A1 (en) | Preparation procedure for panax notoginseng medicinal liquor for oral administration for treating rheumatic ostalgia | |
| CN103933487A (en) | Compound traditional Chinese medicament for treating depression | |
| CN115137778A (en) | Application of traditional Chinese medicine composition in preparation of medicine for improving and/or treating rhinitis | |
| CN105963500B (en) | Traditional Chinese medicine preparation for treating cold and preparation method and detection method thereof | |
| CN102309542A (en) | Orthosiphon n-butanol fraction medicine for treating chronic nephritis and preparation method thereof | |
| CN102188477B (en) | Preparation method and application of active component of radix gentianae extractive | |
| EP2606883A1 (en) | Uses of n-Butylidenephthalide in Treating a Liver Injury and Improving Liver Function | |
| CN101716269A (en) | Traditional Chinese medicine composition for treating hyperpiesia | |
| CN1823982A (en) | Chinese medicinal preparation for liver soothing and speen fortifying and its manufacturing method | |
| CN103349737B (en) | Traditional Chinese medicine composite for treating headache and preparation method of traditional Chinese medicine composite | |
| CN102349926B (en) | New medical application of combination of paeonol, derivative thereof and paeoniflorin | |
| CN107714820B (en) | Pharmaceutical composition for treating allergic rhinitis and preparation method and application thereof | |
| CN107625796B (en) | Pharmaceutical composition containing radix angelicae and application thereof | |
| CN102716231B (en) | A kind of Chinese medicine composition and application thereof for the treatment of brain injury and cerebral edema | |
| CN112717031B (en) | Pharmaceutical composition for treating Alzheimer's disease and preparation method thereof | |
| CN104474040A (en) | Medicine composition for preventing and treating migraine disease, as well as preparation method and application thereof | |
| CN103800449B (en) | A kind of Chinese medicine composition for the treatment of Yin Xu Nei Re Zheng type 2 diabetes mellitus | |
| CN113995782B (en) | Application of composition containing selfheal to preparation of medicine for treating thyroid nodules | |
| CN1283303C (en) | Medicine composition for ischemia apoplexy | |
| CN107536053B (en) | Antiemetic food | |
| CN103120715B (en) | Traditional Chinese medicine composition for preparing medicament for prevention and treatment of focal glomeruloscerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |